Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions
Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions
1. Breast cancer patients and age-matched controls are first invited to answer questions on
 HRQoL.

 2. Among responding breast cancer patients, a subset are invited in a randomized clinical
 trial with two digital interventions for cancer stress management, cognitive based
 stress management (CBSM) and mindfulness based intervention (MBI), as well as a control
 group.

 3. The goal is to determine whether digital CBSM or MBI can effectively reduce stress
 levels as compared to a control group. Second, whether these interventions can improve
 HRQoL (or avoid onset of HRQoL problems) for patients with breast cancer, compared to a
 control group.
After completing the baseline HRQoL assessment, eligible breast cancer patients will be
 invited to participate in a randomized clinical trial.

 Those who are willing will be randomly allocated to one of the following arms: a) Digital
 cognitive based stress management, b) Digital mindfulness based intervention or c) Control
 group.

 The intervention is based on a revised version of the Stressproffen app, which was developed
 by the Oslo University Hospital (Lise Solberg Nes, Elin Børøsund and others).

 Outcome measures include measures of perceived stress and HRQoL.
Inclusion Criteria:

 -  first occurrence breast cancer diagnosed from Jan 1, 2020

 -  non-metastatic cancer stage 0-III

 Invasive tumors must be:

 -  HER2 positive (regardless of ER, PR) or

 -  ER negative

 -  (may later include other ER+ if not conflict with recruitment for EMIT/OPTIMA)

 Exclusion Criteria:

 -  None